EDGEWISE reports Phase 2 HCM trial results for EDG-7500

June 16, 2026 7:00 AM

Edgewise Therapeutics (NASDAQ: EWTX) reported top-line results from the 12-week Phase 2 Part D CIRRUS-HCM trial of EDG-7500, an oral ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found